Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Forge Biologics Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action constitutes the entirety of the company's active prosecution workload. The data indicates that 1 distinct examiner is overseeing the matter, which centralizes the interaction between the company and the patent office. Furthermore, the involvement of 1 distinct art unit confirms that the technical subject matter is being evaluated within a specific specialized group.
The busiest examiner for Forge Biologics Inc. is BEHARRY, ZANNA MARIA, who is assigned 1 busiest examiner pending office action. As this is the only pending action for the portfolio, the examiner's individual perspective will be the primary factor in the current prosecution. For a practitioner, this concentration suggests that a deep understanding of this examiner's specific history and the 1 distinct art unit's standards is essential. The alignment of 1 distinct examiner with the 1 pending office action simplifies the management of the portfolio but increases the importance of successfully navigating this examiner's requirements.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BEHARRY, ZANNA MARIA | 1 | 24.7% | +56.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560651 | ADENOVIRAL HELPER PLASMID | BEHARRY, ZANNA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560651 | ADENOVIRAL HELPER PLASMID | BEHARRY, ZANNA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560651 | ADENOVIRAL HELPER PLASMID | BEHARRY, ZANNA MARIA | 1632 | §102§103§112 | Non-Final OA | — | Pending | Nov 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial